Kojin Therapeutics

Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.

Domain

kojintx.com

Industry

Biopharma

Employees

11-50

Last Funding

$60.0M

Founded

2019

Frequently Asked Questions

What technologies does Kojin Therapeutics use?+

Kojin Therapeutics uses 8 technologies including Google Analytics, Google Tag Manager, Cloudflare.

What industry is Kojin Therapeutics in?+

Kojin Therapeutics operates in the Biopharma industry.

Where is Kojin Therapeutics based?+

Kojin Therapeutics is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026